Product Name
HTRA1, siRNA
Full Product Name
HTRA1 siRNA (Human)
Product Synonym Names
HTRA; PRSS11; Serine protease HTRA1; High-temperature requirement A serine peptidase 1; L56; Serine protease 11
Product Gene Name
HTRA1 sirna
[Similar Products]
Research Use Only
For Research Use Only. Not for use in diagnostic procedures.
3D Structure
ModBase 3D Structure for Q92743
Specificity
HTRA1 siRNA (Human) is a target-specific 19-23 nt siRNA oligo duplexes designed to knock down gene expression.
Purity/Purification
> 97%
Form/Format
Lyophilized powder
Quality Control
Oligonucleotide synthesis is monitored base by base through trityl analysis to ensure appropriate coupling efficiency. The oligo is subsequently purified by affinity-solid phase extraction. The annealed RNA duplex is further analyzed by mass spectrometry to verify the exact composition of the duplex. Each lot is compared to the previous lot by mass spectrometry to ensure maximum lot-to-lot consistency.
Directions for Use
We recommends transfection with 100 nM siRNA 48 to 72 hours prior to cell lysis. Before resuspending, briefly centrifuge the tube to ensure the lyophilized siRNA is at the bottom of the tube. Resuspend the siRNA oligos to an appropriate concentration with DEPC water. For each vial, suitable for 250 transfections in 24 well plate (20 pmol for each well).
Components
We offer pre-designed sets of 3 different target-specific siRNA oligo duplexes of human HTRA1 gene. Each vial contains 5 nmol of lyophilized siRNA. The duplexes can be transfected individually or pooled together to achieve knockdown of the target gene, which is most commonly assessed by qPCR or western blot. Our siRNA oligos are also chemically modified (2'-OMe) at no extra charge for increased stability and enhanced knockdown in vitro and in vivo.
Preparation and Storage
Shipped at 4 degree C. Store at -20 degree C for one year.
Negative Control
siRNA Negative Control (Catalog# MBS8241404) is a non-targeting 21 nt siRNA recommended as a negative control for experiments using targeted siRNA transfection.
Other Notes
Small volumes of HTRA1 sirna vial(s) may occasionally become entrapped in the seal of the product vial during shipment and storage. If necessary, briefly centrifuge the vial on a tabletop centrifuge to dislodge any liquid in the container`s cap. Certain products may require to ship with dry ice and additional dry ice fee may apply.
Related Product Information for
HTRA1 sirna
siRNA to inhibit HTRA1 expression using RNA interference
Applications Tested/Suitable for HTRA1 sirna
RNA Interference (RNAi)
NCBI/Uniprot data below describe general gene information for HTRA1. It may not necessarily be applicable to this product.
NCBI Accession #
NP_002766.1
[Other Products]
NCBI GenBank Nucleotide #
NM_002775.4
[Other Products]
UniProt Primary Accession #
Q92743
[Other Products]
UniProt Secondary Accession #
Q9UNS5; D3DRE4[Other Products]
UniProt Related Accession #
Q92743[Other Products]
Molecular Weight
51,287 Da
NCBI Official Full Name
serine protease HTRA1
NCBI Official Synonym Full Names
HtrA serine peptidase 1
NCBI Official Symbol
HTRA1 [Similar Products]
NCBI Official Synonym Symbols
L56; HtrA; ARMD7; ORF480; PRSS11; CARASIL
[Similar Products]
NCBI Protein Information
serine protease HTRA1
UniProt Protein Name
Serine protease HTRA1
UniProt Synonym Protein Names
High-temperature requirement A serine peptidase 1; L56; Serine protease 11
Protein Family
Serine protease
UniProt Gene Name
HTRA1 [Similar Products]
UniProt Synonym Gene Names
HTRA; PRSS11 [Similar Products]
UniProt Entry Name
HTRA1_HUMAN
NCBI Summary for HTRA1
This gene encodes a member of the trypsin family of serine proteases. This protein is a secreted enzyme that is proposed to regulate the availability of insulin-like growth factors (IGFs) by cleaving IGF-binding proteins. It has also been suggested to be a regulator of cell growth. Variations in the promoter region of this gene are the cause of susceptibility to age-related macular degeneration type 7. [provided by RefSeq, Jul 2008]
UniProt Comments for HTRA1
HTRA1: Serine protease with a variety of targets, including extracellular matrix proteins such as fibronectin. HTRA1-generated fibronectin fragments further induce synovial cells to up-regulate MMP1 and MMP3 production. May also degrade proteoglycans, such as aggrecan, decorin and fibromodulin. Through cleavage of proteoglycans, may release soluble FGF-glycosaminoglycan complexes that promote the range and intensity of FGF signals in the extracellular space. Regulates the availability of insulin-like growth factors (IGFs) by cleaving IGF-binding proteins. Inhibits signaling mediated by TGF-beta family members. This activity requires the integrity of the catalytic site, although it is unclear whether TGF-beta proteins are themselves degraded. By acting on TGF-beta signaling, may regulate many physiological processes, including retinal angiogenesis and neuronal survival and maturation during development. Intracellularly, degrades TSC2, leading to the activation of TSC2 downstream targets. Variations in the promoter region of HTRA1 are the cause of susceptibility to age-related macular degeneration type 7 (ARMD7). ARMD is the leading cause of vision loss and blindness among older individuals in the developed word. It is classified as either dry (nonneovascular) or wet (neovascular). ARMD7 is a wet form, in which new blood vessels form and break beneath the retina. This leakage causes permanent damage to surrounding retinal tissue, distorting and destroying central vision. Wet ARMD is more prevalent among Asians than Caucasians. Defects in HTRA1 are the cause of cerebral autosomal recessive arteriopathy with subcortical infarcts and leukoencephalopathy (CARASIL). CARASIL is characterized by nonhypertensive cerebral small-vessel arteriopathy with subcortical infarcts, alopecia, and spondylosis, with an onset in early *****hood. On neuropathological examination, atherosclerosis associated with intimal thickening and dense collagen fibers, loss of vascular smooth-muscle cells, and hyaline degeneration of the tunica media has been observed in cerebral small arteries. Belongs to the peptidase S1B family.
Protein type: Secreted; EC 3.4.21.-; Secreted, signal peptide; Protease
Chromosomal Location of Human Ortholog: 10q26.3
Cellular Component: extracellular matrix; extracellular space; cytosol
Molecular Function: insulin-like growth factor binding; serine-type peptidase activity; serine-type endopeptidase activity
Biological Process: regulation of cell growth; negative regulation of defense response to virus; proteolysis; negative regulation of transforming growth factor beta receptor signaling pathway; positive regulation of epithelial cell proliferation; negative regulation of BMP signaling pathway
Disease: Macular Degeneration, Age-related, 7; Cerebral Autosomal Recessive Arteriopathy With Subcortical Infarcts And Leukoencephalopathy
Research Articles on HTRA1
1. Gene variants in CFH, ARMS2 and HTRA1 are related to an increased risk of age-related macular degeneration in a northern Chinese population.
Precautions
All of MyBioSource's Products are for scientific laboratory research purposes and are not for diagnostic, therapeutics, prophylactic or in vivo use. Through your purchase, you expressly represent and warrant to MyBioSource that you will properly test and use any Products purchased from MyBioSource in accordance with industry standards. MyBioSource and its authorized distributors reserve the right to refuse to process any order where we reasonably believe that the intended use will fall outside of our acceptable guidelines.
Disclaimer
While every efforts were made to ensure the accuracy of the information provided in this datasheet, MyBioSource will not be liable for any omissions or errors contained herein. MyBioSource reserves the right to make changes to this datasheet at any time without prior notice.
It is the responsibility of the customer to report product performance issues to MyBioSource within 30 days of receipt of the product. Please visit our Terms & Conditions page for more information.
